Abstract
Although cyclin-dependent kinase inhibitors of the Cip/Kip family were the first to be discovered in mammalian cells, and they are the best characterized to date, fundamental mysteries remain concerning their biological roles and their regulation. The family, consisting so far of three members, is characterized by a C-terminal Cdk-inhibitory domain with a shared core homology and unrelated C-terminal domains of varying size (Lee et al. 1995; Matsuoka et al. 1995). To date, a function has been ascribed to the C-terminal domain of only one member of the family. The C terminus of the p21 has been shown to be able to bind and inactivate the function of the DNA polymerase-δ processivity factor, PCNA (J. Chen et al. 1995, 1996a, b; Goubin and Ducommun 1995; Luo et al. 1995; Nakanishi et al. 1995b; Warbrick et al. 1995; Waga et al. 1994).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Agrawal D, Hauser P, McPherson F, Dong F, Garcia A, Pledger WJ (1996) Repression of p27kip1 synthesis by platelet-derived growth factor in BALB/c 3T3 cells. Mol Cell Biol 16: 4327–4336
Aprelikova O. Xiong Y, Liu ET (1995) Both p 1 and p21 families of cyclin-dependent kinase ( CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J Biol Chem 270: 18195–18197
Artuso M, Esteve A, Bresil H, Vuillaume M, Hall J (1995) The role of the Ataxia telangiectasia gene in the p53, WAFI/CIPI(p21)- and GADD45-mediated response to DNA damage produced by ionising radiation. Oncogene I1: 1427–1435
Bae I, Fan S, Bhatia K, Kohn KW, Fornace AJ, O’Connor PM (1995) Relationships between GI arrest and stability of the p53 and p2lCipl/Wafl proteins following gamma-irradiation of human lymphoma cells. Cancer Res 55: 2387–2393
Barboule N, Mazars P, Baldin V, Vidal S, Jozan S, Martel P, Valette A (1995) Expression of p2I WAFT/ CIPI is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Intl Cancer 63: 611–615
Bates S, Vousden KH (1996) p53 in signalling checkpoint arrest or apoptosis. Curr Opin Genet Dev 6: 12–18
Bhatia K, Fan S, Spangler G, Weintraub M, O’Connor PM, Judde JG, Magrath I (1995) A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt’s lymphoma. Cancer Res 55: 1431–1435
Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon G.1 (1995) Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552–557
Bullrich F, MacLachlan TK, Sang N, Druck T, Veronese ME, Allen SL, Chiorazzi N, Koff A, Heubner K, Croce CM, et al. (1995) Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kipl, to regions involved in human cancer. Cancer Res 55: 1199–1205
Chen IT, Akamatsu M, Smith ML, Lung FD, Duba D, Roller PP, Fornace AJ, O’Connor PM (1996a) Characterization of p2lCipl/Wafl peptide domains required for cyclin E/Cdk2 and PCNA interaction. Oncogene 12: 595–607
Chen J, Jackson PK, Kirschner MW, Dutta A (1995) Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374: 386–388
Chen J, Peters R, Saha P, Lee P, Theodoras A, Pagano M, Wagner G, Dutta A (1996b) A 39 amino acid fragment of the cell cycle regulator p2I is sufficient to bind PCNA and partially inhibit DNA replication in vivo. Nucleic Acids Res 24: 1727–1733
ChenJ, Saha P, Kornbluth S, Dynlacht B, Dutta A (1996e) Cyclin-binding motifs are essential for the function of p21kip1. Mol Cell Biol 19: 4673–4682
Chen J, Willingham T, Shuford M, Nisen PD (1996d) Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27KIP1. J Clin Invest 97: 1983–1988
Coats S, Flanagan WM, Nourse J, Roberts JM (1996) Requirement of p27kip1 for restriction point control of the fibroblast cell cycle. Science 272: 877–880
Deng C, Zhang P, Harper JW, Elledge SJ, Leder P (1995) Mice lacking p21CIPI/WAFT undergo normal development, but are defective in GI checkpoint control. Cell 82: 675–684
Dulic V, Kaufmann WK, Wilson Si, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI (1994) p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced GI arrest. Cell 76: 1013–1023
EI-Deiry W, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAFT, a potential mediator of p53 tumor suppression. Cell 75: 817–825
EI-Deiry W, Harper JW, O’Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, et al. (1994) WAFI/CIPI is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169–1174
Ezhevsky SA, Toyoshima H, Hunter T, Scott DW (1996) Role of cyclin A and p27 in anti-IgM-induced GI growth arrest of murine B-cell lymphomas. Mol Biol Cell 7: 553–564
Fang F, Orend G, Watanabe N, Hunter T, Ruoslahti E (1996) Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science 271: 499–502
Fero ML, Rivkin M, Tasch M, Porter P. Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM (1996) A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kipl)-deficient mice. Cell 85: 733–744
Ferrando AA, Balbin M, Pendas AM, Vizoso F, Velasco G, Lopez-Otin C (1995) Mutational analysis of the human cyclin-dependent kinase inhibitor p27K’rj in primary breast carcinomas. Hum Genet 967: 91–94
Fotedar R, Fitzgerald P, Rousselle T, Cannella D, Doree M. Messier H, Fotedar A (1996) p2I contains independent binding sites for cyclin and cdk2:both sites are required to inhibit cdk2 kinase activity. Oncogene 12: 2155–2164
Gao X, Chen YQ, Wu N. Grignon DJ, Sakr W, Porter AT, Honn KV (1995) Somatic mutations of the WAFI/CIPI gene in primary prostate cancer. Oncogene 11: 1395–1398
Goubin F, Ducommun B (1995) Identification of binding domains on the p2lCipl cyclin-dependent kinase inhibitor. Oncogene 10: 2281–2287
Gu Y, Turck CW, Morgan DO (1993) Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366: 707–710
Gulbis JM, Kelman Z, Hurwitz J, O’Donnel M, Kuriyan, J (1996) Structure of the C-terminal region of p2lwar /Ci~~ complexed with human PCNA. Cell 87: 297–306
Guo K, Wang J, Andres V, Smith RC, Walsh K (1995) MyoD-induced expression of p21 inhibits cyclin- dependent kinase activity upon myocyte terminal differentiation. Mol Cell Biol 15: 3823–3829
Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lassar AB (1995) Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267: 1018–1021
Hall M, Bates S, Peters G (1995) Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 11: 1581–1588
Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge S J (1993) The p21 Cdk-interacting protein Cipl is a potent inhibitor of GI cyclin-dependent kinases. Cell 75: 805–816
Harper JW, Elledge SJ, Keyomarsi K et al. (1995) Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6: 387–400
Hatada I, Mukai T (1995) Genomic imprinting of p57KIP2, a cyclin-dependent kinase inhibitor, in mouse. Nat Genet 11: 204–206
Hengst L, Reed SI (1996) Translational control of p27Kipl accumulation during the cell cycle. Science 271: 1861–1864
Hengst L, Dulic V, Slingerland JM, Lees E, Reed SI (1994) A cell cycle-regulated inhibitor of cyclindependent kinases. Proc. Natl Acad Sci USA 91: 5291–5295
Hirama T, Koefer HP (1996) Role of cyclin-dependent kinase inhibitors in the development of cancer. Blood 86: 841–854
Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253: 49–53
Kastan MB, Zhan Q, EI-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia telangiectasia. Cell 71: 587–597
Kato JY, Matsuoka M, Polyak K. Massague J, Sherr CJ (1994) Cyclic AMP-induced GI phase arrest mediated by an inhibitor (p27Kipl) of cyclin-dependent kinase 4 activation. Cell 79: 487–496
Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilcyznski S, et al. (1995) Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/ Kip1 in human malignancies. Cancer Res 55: 2266–2269
Kawamata N, Seriu T, Koeffler HP, Bartram CR (1996) Molecular analysis of the cyclin-dependent kinase inhibitor family: p16(CDKN2/MTSI/INK4A), p18(INK4C) and p27(Kipl) genes in neuroblastomas. Cancer 77: 570–575
Kiwacki RW, Hengst L, Tennant L, Reed SI, Wright PE (1996) Structural studies of p21 Wafl/Cipl/Sdil in the free and Cdk2 bound state: conformational disorder mediates binding diversity. Proc Natl Acad Sci USA 93: 11504–11507
Kiyokawa H, Kineman RD, Manova TK, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A (1996) Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 85: 721–732
Kondo M, Matsuoka S. Uchida K, Osada H, Nagatake M, Takagi K, Harper JW, Takahashi T, Elledge SJ, Takahashi T (1996) Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5. Oncogene 12: 1365–1368
Kranenburg O, Scharnhorst V, Van der Eb A, Zantema A (1995) Inhibition of cyclin-dependent kinase activity triggers neuronal differentiation of mouse neuroblastoma cells. J Cell Biol 131: 227–234
Lee MH, Reynisdottir I, Massague J (1995) Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9: 639–649
Lee MH, Nikolic M, Baptista CA, Lai E, Tsai LH, Massague J (1996) The brain-specific activator p35 allows CdkS to escape inhibition by p27Kip1 in neurons. Proc Natl Acad Sci USA 93: 3259–3263
Levine AJ, Momand J, Finlay CA (1991) The p53 tumor suppressor gene. Nature 351: 453–456
Li R, Waga S, Hannon GJ, Beach D. Stillman B (1994) Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371: 534–537
Li R, Hannon GJ, Beach D, Stillman B (1996) Subcellular distribution of p21 and PCNA in normal and repair-deficient cells following DNA damage. Curr Biol 6: 189–199
Liu M, Felling JC (1995) UV-B/A irradiation of mouse keratinocytes results in p53-mediated WAFT/ CIP I expression. Oncogene 10: 1955–1960
Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP (1996) Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10: 142–153
Luo Y, Hurwitz J, Massague J (1995) Cell-cycle inhibition by independent CDK and PCNA binding domains in p2lCipl. Nature 375: 159–161
Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T (1995) p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9: 935–944
Mal A, Poon R, Howe PH, Toyoshima H, Hunter T, Harter ML (1996) Inactivation of p27K’Pl by the viral EIA oncoprotein in TGF-(3 treated cells. Nature 380: 262–265
Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ (1995) p57KIP2, a structurally distinct member of the p21CIPl Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9: 650–662
Matsuoka S, Thompson JS, Edwards MC, Barletta JM, Grundy P, Kalikin LM, Harper JW, Elledge Si, Feinberg AP (1996) Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57kip2, on chromosome 11p15. Proc Natl Acad Sci USA 93: 3026–3030
McDonald ER, Wu GS, Waldman T, El Deiry WS (1996) Repair defect in p21 WAFI/CIPI-/- human cancer cells. Cancer Res 56: 2250–2255
Medrano EE, Im S, Yang F, Abdel MZ (1995) Ultraviolet B light induces GI arrest in human melanocytes by prolonged inhibition of retinoblastoma protein phosphorylation associated with long-term expression of the p21Waf-1/SDI-I/Cip-1 protein. Cancer Res 55: 4047–4052
Nakanishi M, Robetorye RS, Adami GR, Pereira SO, Smith JR (1995a) Identification of the active region of the DNA synthesis inhibitory gene p2lSdil/CIPI/WAFI. Embo J 14: 555–563
Nakanishi M, Robetorye RS, Pereira SO, Smith JR (1995b) The C-terminal region of p21SD11/WAF1/ CIPI is involved in proliferating cell nuclear antigen binding but does not appear to be required for growth inhibition. J Biol Chem 270: 17060–17063
Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K (1996) Mice lacking p27(Kipl) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707–720
Noda A, Ning Y, Venable SF, Pereira SO, Smith.JR (1994) Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211: 90–98
Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts JM (1994) Interleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372: 570–573
Orlow I, Iavarone A, Crider-Miller SJ, Bonilla F, Latres E, Lee M-H, Gerald WL, Massague J, Weissman BE, Cordon-Cardo C (1996) Cyclin-dependent kinase inhibitor, p57Kip2 in soft tissue sarcomas and Wilm’s tumors. Cancer Res 56: 1219–1221
Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M (1995) Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682–685
Pan ZQ, Reardon JT, Li L, Flores RH, Legerski R, Sancar A, Hurwitz J (1995) Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21. J Biol Chem 270: 22008–22016
Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW, Elledge SJ (1995) p53-independent expression of p2lCipl in muscle and other terminally differentiating cells. Science 267: 1024–1027
Petrocelli T, Poon R, Drucker DJ, Slingerland JM, Rosen CF (1996) UVB radiation induces p2lCipl/ WAFT and mediates GI and S phase checkpoints. Oncogene 12: 1387–1396
Pietenpol JA, Bohlander SK, Sato Y, Papadopoulos N, Liu B, Friedman C, Trask BJ, Roberts JM, Kinzler KW, Rowley JD et al. (1995) Assignment of the human p27Kipl gene to 12p13 and its analysis in leukemias. Cancer Res 55: 1206–1210
Podust VN, Podust LM, Goubin F, Ducommun B, Hubscher U (1995) Mechanism of inhibition of proliferating cell nuclear antigen-dependent DNA synthesis by the cyclin-dependent kinase inhibitor p21. Biochemistry 34: 8869–8875
Pollock PM, Pearson JV, Hayward NK (1996) Compilation of somatic mutations of the CDKN2 gene in human cancers:non-random distribution of base substitutions. Genes Chrom Cancer 15: 77–88
Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A (1994a) p27Kipl, a cyclinCdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8: 9–22
Polyak K, Lee MH, Erdjument BH, Koff A, Roberts JM, Tempst P, Massague J (1994b) Cloning of p27Kipl. a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59–66
Ponce CM, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery K, Mathew S, Krauter K, Sheinfeld J, Massague J, Cordon-Cardo C (1995) p27Kipl: chromosomal mapping to 12p12–12p13.1 and absence of mutations in human tumors. Cancer Res 55: 1211–1214
Poon RY, Toyoshima H, Hunter T (1995) Redistribution of the CDK inhibitor p27 between different cyclin-CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. Mol Biol Cell 6: 1197–1213
Reid LH, Crider-Miller SJ, West A, Lee M.-H, Massague J, Weissman BE (1996) Genomic organization of human p57Kip2 gene and its analysis in the G401 Wilm’s tumor assay. Cancer Res 56: 1214–1218
Resnitzky D, Hengst L, Reed SI (1995) Cyclin A-associated kinase complex activity is rate limiting for entrance into S phase and is negatively regulated in GI by p27K’°. Mol Cell Biol 15: 4347–4352
Reynisdottir I, Polyak K, Iavarone A, Massague J (1995) Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 9: 1831–1845
Russo AA, Jeffrey PD, Patten AK, Massague J, Pavletich NP (1996) Crystal structure of the p27 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382: 325–331
Schulze A, Zerfass-Thome K, Berges J, Middendorf S, Jansen-Duerr P, Henglein B (1996) Anchorage-dependent transcription of the cyclin A gene. Mol Cell Biology 16: 4632–4638
Serrano M, Lee H-W, Chin L, Cordon-Cardo C, Beach D, DePinho RA (1996) Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27–37
Shivji MK, Grey SJ, Strausfeld UP, Wood RD, Blow JJ (1994) Cipl inhibits DNA replication but not PCNA-dependent nucleotide excision-repair. Current Biology 4: 1062–1068
Shou W, Dunphy WG (1996) Cell cycle control by Xenopus p28kipa developmentally regulated inhibitor of cyclin dependent kinases. Mol Biol Cell 7: 457–469
Skapek SX, Rhee J, Spicer DB, Lassar AB (1995) Inhibition of myogenic differentiation in proliferating myoblasts by cyclin DI-dependent kinase. Science 267: 1022–1024
Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI (1994) A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. Mol Cell Biol 14: 3683–3694
Soos TJ, Kiyokawa H, Yan JS, Rubin MS, Giordano A, DeBlasio A, Bottega S, Wong B, Mendelsohn J, Koff A (1996) Formation of p27-Cdk complexes during the human mitotic cell cycle. Cell Growth Diff 7: 135–146
Su JY, Rempel RE, Erikson E, Mailer JL (1995) Cloning and characterization of the Xenopus cyclindependent kinase inhibitor p27kip1. Proc Natl Acad Sci USA 92: 10187–10191
Sun Y, Hildesheim A, Li H, Li Y, Chen JY, Cheng YI, Hayes RB, Rothman N, Bi WF, Cao Y et al. (1995) No point mutation but a codon 31serarg polymorphism of the WAF-1/CIP-1/p21 tumor suppressor gene in nasopharyngeal carcinoma (NPC): the polymorphism distinguishes Caucasians from Chinese. Cancer Epidemiol Biomarkers Prey 4: 261–267
Takeuchi S, Mori N, Koike M, Slater J, Park S, Miller CW, Miyoshi I, Koeffler, HP (1996) Frequent loss of heterozygosity in region of the KIPI locus in non-small cell lung cancer: evidence for a new tumor suppressor gene on the short arm of chromosome 12. Cancer Res 56: 738–740
Toyoshima H, Hunter T (1994) p27, a novel inhibitor of GI cyclin-Cdk protein kinase activity, is related to p21. Cell 78: 67–74
Vidal MJ, Loganzo FJ, de Oliveira AR, Hayward NK, Albino AP (1995) Mutations and defective expression of the WAFT p21 tumour-suppressor gene in malignant melanomas. Melanoma Res 5: 243–250
Waga S, Hannon GJ, Beach D, Stillman B (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574–578
Waldman T, Kinzler KW, Vogelstein B (1995) p21 is necessary for the p53-mediated GI arrest in human cancer cells. Cancer Res 55: 5187–5190
Wang QM, Jones JB, Studzinski GP (1996) Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 56: 264–267
Warbrick E. Lane DP, Glover DM, Cox LS (1995) A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21 WAFI and proliferating cell nuclear antigen. Curr Biol 5: 275–282
Watanabe H, Fukuchi K, Takagi Y, Tomoyasu S, Tsuruoka N, Gomi K (1995) Molecular analysis of the Cipl/Waft (p21) gene in diverse types of human tumors. Biochim Biophys Acta 1263: 275–280
Winston J, Dong F, Pledger WJ (1996) Differential modulation of GI cyclins and the Cdk inhibitor p27kip1 by platelet-derived growth factor and plasma factors in density-arrested fibroblasts. J Biol Cheri 271: 11253–11260
Xiong Y, Zhang H, Beach D (1992) D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71: 505–514
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D (1993a) p21 is a universal inhibitor of cyclin kinases. Nature 366: 701–704
Xiong Y, Zhang H, Beach D (1993b) Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 7: 1572–1583
Zhang H, Xiong Y, Beach, D. (1993) Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell 4: 897–906
Zhang H, Hannon GJ, Beach D (1994a) p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 8: 1750–1758
Zhang H, Hannon GJ, Casso D, Beach D (1994b) p21 is a component of active cell cycle kinases. Cold Spring Harb Symp Quant Biol 59: 21–29
Zhu X, Ohtsubo M, Bohmer RM, Roberts JM, Assoian RK (1996) Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J Cell Biol 133: 391–403
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Hengst, L., Reed, S.I. (1998). Inhibitors of the Cip/Kip Family. In: Vogt, P.K., Reed, S.I. (eds) Cyclin Dependent Kinase (CDK) Inhibitors. Current Topics in Microbiology and Immunology, vol 227. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71941-7_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-71941-7_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-71943-1
Online ISBN: 978-3-642-71941-7
eBook Packages: Springer Book Archive